Effect of glycocalyx-targeted therapy on vascular function in older adults: a randomized controlled trial

• Published in: Journal of applied physiology (1985) Vol. 136; no. 6; p. 1488
• Main Authors: Gimblet, Colin J, Ernst, Jackson W, Bell, Blair, Bos, Kyle D, Stroud, Amy K, Wendt, Linder H, Donato, Anthony J, Jalal, Diana I, Pierce, Gary L
• Format: Journal Article
• Language: English
• Published: United States American Physiological Society 01.06.2024
• Subjects: Adults; Aged; Antihypertensives; Brachial Artery - diagnostic imaging; Brachial Artery - drug effects; Brachial Artery - physiology; Cardiovascular diseases; Cardiovascular Diseases - drug therapy; Cardiovascular Diseases - physiopathology; Disease control; Double-Blind Method; Endothelium, Vascular - drug effects; Endothelium, Vascular - physiology; Endothelium, Vascular - physiopathology; Female; Glycocalyx - drug effects; Glycocalyx - metabolism; Health risks; Humans; Male; Middle Aged; Older people; Placebos; Risk management; Shear rate; Supplements; Thickness measurement; Vasodilation - drug effects; Vasodilation - physiology; glycocalyx; endothelium; endocalyx
• DOI: 10.1152/japplphysiol.00150.2024
• ISSN: 8750-7587; 1522-1601

Advancing age increases cardiovascular disease risk, in part, because of impaired glycocalyx thickness and endothelial dysfunction. Glycocalyx-targeted therapies, such as Endocalyx Pro, could improve both glycocalyx thickness and endothelial function in older adults; however, this has yet to be tested. We hypothesized that Endocalyx Pro supplementation would increase glycocalyx thickness and endothelial function in older adults. Twenty-three older adults aged 66 ± 7 yr (52% female) were enrolled in a randomized, double-blind, placebo-controlled, parallel-arms study to investigate the effect of 12-wk Endocalyx Pro supplementation (3,712 mg/day) on glycocalyx thickness and endothelial function. Glycocalyx thickness was assessed using the GlycoCheck, and endothelial function was determined via brachial artery flow-mediated dilation (FMD). Between-group comparisons revealed Endocalyx Pro did not increase glycocalyx thickness in microvessels 4-25 µm ( = 0.33), 4-7 µm ( = 0.07), or 10-25 µm ( = 0.47) in diameter when compared with placebo. In addition, Endocalyx Pro did not significantly improve FMD [mean ratio (95%) confidence interval [CI]) for between-group comparisons, 1.16 (0.77-1.74); = 0.48]. However, Endocalyx Pro improved FMD normalized to shear rate (SR) area under the curve [mean ratio (95% CI) for between-group comparisons, 2.41 (1.14,4.13); = 0.001]. Moreover, Endocalyx Pro increased capillary glycocalyx thickness more than placebo in individuals not taking antihypertensive medication [mean difference (95% CI) for between-group comparison, -0.08 (-0.15, -0.01); = 0.02]. Our pilot study suggests that Endocalyx Pro supplementation is feasible in older adults but has no measurable effect on overall glycocalyx thickness and FMD. However, Endocalyx Pro may have select effects on capillary glycocalyx thickness and FMD normalized to shear rate among older adults, but further investigation is warranted. Endothelial glycocalyx thickness and vascular endothelial function decline with advancing age. Endocalyx Pro is a glycocalyx-targeted therapy that may improve endothelial glycocalyx thickness and vascular endothelial function in older adults. This study demonstrated that 12-wk Endocalyx Pro supplementation did not improve overall endothelial glycocalyx thickness or flow-mediated dilation in older adults; however, Endocalyx Pro did increase capillary glycocalyx thickness in individuals not taking antihypertensive medication and improve flow-mediated dilation normalized to the shear stimulus.